KRAS and non-small cell lung carcinoma: The goal of this review is to add valuable information on the use of immunotherapy in NSCLC with actionable alterations in genes including ALK, ROS1, BRAF, c-MET, RET, NTRK, KRAS, and HER2. Epidermal growth factor receptor (EGFR) mutations are not included in this review as they are included in another manuscript by our group which was submitted separately.